Octapharma to invest EUR 21 million in multi-use facility in Springe, Germany

Octapharma confirmed a EUR 21 million investment to build a new multi-function facility in Springe, Germany, including a new production line for human normal immunoglobulin panzyga and increased capacity for human albumin albunorm. Completion is expected in 2019.

“This multi-function building plays an important role for the growth strategy of Octapharma worldwide, but especially at the site in Springe, Germany, as it allows us to establish a new product line without affecting the current production.”octapharma.com

• 1 source
• octapharma.comOctapharma to build new multi-use venueFeb 21, 2020

Summarized from public sources; check the original articles before acting on it.